Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Viatris Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between August 8, 2024, and February 26, 2025, and aims to address misleading information provided by Viatris regarding the failed inspection of its Indore, India facility [1][4]. - Defendants allegedly downplayed the impact of an FDA Warning Letter, which restricted the shipment of eleven products from the Indore facility, referring to it as a "minor headwind" [4][6]. - The lawsuit claims that Viatris did not disclose critical information about the inspection timeline, remediation efforts, and the financial implications of the Warning Letter, leading to artificially inflated stock prices for investors [5][6]. Group 2: Investor Actions - Investors who purchased Viatris securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for June 3, 2025 [3][8]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class [9].

Core Viewpoint - The Viatris class action lawsuit alleges that the company and its executives misrepresented the impact of regulatory issues on its financial outlook, leading to significant stock price declines following disappointing earnings guidance [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Quinn v. Viatris Inc., and it involves purchasers of Viatris securities from August 8, 2024, to February 26, 2025, with a deadline of June 3, 2025, for lead plaintiff applications [1]. - The lawsuit claims that Viatris downplayed the ramifications of a failed FDA inspection at its Indore facility, which significantly affected its revenue outlook and growth projections [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris' stock price dropped by over 15% on February 27, 2025 [4]. Group 2: Company Background - Viatris is described as a global healthcare company facing challenges related to regulatory compliance and product manufacturing [2]. - The law firm Robbins Geller Rudman & Dowd LLP, which is leading the class action, has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represe ...

LOS ANGELES, April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the "Class Period"), are ...

PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team.Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Viatris A ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Viatris Inc. securities during the specified Class Period, indicating potential legal issues related to the company's disclosures and the impact of regulatory actions on its financials [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between August 8, 2024, and February 26, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiff must file a motion by June 3, 2025, and a lead plaintiff acts on behalf of other class members in directing the litigation [3]. Group 2: Allegations Against Viatris - The lawsuit claims that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that restricted the shipment of eleven products [5][6]. - Defendants allegedly downplayed the significance of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection timeline, remediation efforts, and the financial implications of the warning letter on Viatris' operations [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes its experience and success in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability to represent investors effectively [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth [5][6]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Viatris between August 8, 2024, and February 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Viatris, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Viatris - The complaint alleges that Viatris and its executives made false and misleading statements regarding the company's financial outlook and downplayed the significance of a failed FDA inspection at its Indore facility [5]. - The lawsuit claims that the impact of the failed inspection and subsequent remediation efforts significantly affected Viatris' projected fiscal year 2025 finances, particularly regarding the manufacturing and shipping of key products like Lenalidomide [5]. Group 3: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for the fourth quarter and full fiscal year 2024, attributing below-expectation guidance to the impact of the Indore facility warning letter and import alert [6]. - Following this announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [7].

SAN DIEGO, April 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit.  Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris' top executives with violations of ...

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [2]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024 on February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].